Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
9MW2821 + toripalimab
- Development stage
- Unknown
- Lead developer
- Mabwell
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**9MW2821 + toripalimab** is an investigational combination therapy under clinical development for the treatment of locally advanced or metastatic urothelial carcinoma. 9MW2821 is a novel antibody-drug conjugate (ADC) targeting Nectin-4, a cell surface adhesion molecule overexpressed in several cancers, and delivers a cytotoxic MMAE payload to Nectin-4 positive tumor cells. Toripalimab is a recombinant, humanized monoclonal antibody against PD-1, functioning as an immune checkpoint inhibitor by blocking the interaction of PD-1 with its ligands, thereby restoring T-cell immune response against cancer cells. Both agents are administered via intravenous infusion and have demonstrated promising efficacy and tolerable safety profiles in early-phase clinical studies in treatment-naïve patients with locally advanced or metastatic urothelial carcinoma[1][2][4][5][6].
- Brand names
- Loqtorzi
- Other names
- 9MW2821 plus toripalimabtoripalimab-tpzi + 9MW2821
02
Targets
TUBB (Tubulin (alpha and beta subunits))PVRL4 (Nectin cell adhesion molecule 4)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on 9MW2821 + toripalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 9MW2821 + toripalimab.